1 UnityPoint Health-St. Luke’s, Pharmacy Department, 2720 Stone Park, Boulevard, Sioux City, IA 51104, USA.
2 Sanford USD Medical Center, Pharmacy Department,1305 W18th St., Sioux Falls, SD 57117-5039; USA.
International Journal of Science and Research Archive, 2021, 02(01), 143-148.
Article DOI: 10.30574/ijsra.2021.2.1.0040
DOI url: https://doi.org/10.30574/ijsra.2021.2.1.0040
Received on 03 February 2021; revised on 09 March 2021; accepted on 11 March 2021
Previous studies have shown a correlation between acute kidney injury (AKI) and combination antimicrobial therapy comprising piperacillin-tazobactam and vancomycin. In this study, AKIs were compared in patients who received vancomycin plus piperacillin-tazobactam with those who received vancomycin plus cefepime. We found a statistically significant increase in AKI risk in the vancomycin plus piperacillin-tazobactam group when compared to the vancomycin plus cefepime group using both AKI criteria [KDIGO 18.9% vs. 4.5% (p = 0.0012); RIFLE 11.2% vs. 1.8% (p = 0.0029)]. Vancomycin in combination with piperacillin-tazobactam led to an increased risk of AKI in comparison to vancomycin and cefepime.
Vancomycin Plus Piperacillin-Tazobactam; Vancomycin Plus Cefepime; AKI; KDIGO; RIFLE; Nephrotoxicity; Antibiotics, Antimicrobials
Preview Article PDF
Sydney Jean Rechtenbaugh, Fekadu Fullas, Kimberly Ann Zellmer, Joseph Michael Buren, Corey James Thieman, and Michael Theodore Padomek. Assessing the incidence of acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy compared to that of vancomycin and cefepime. International Journal of Science and Research Archive, 2021, 02(01), 143-148. https://doi.org/10.30574/ijsra.2021.2.1.0040
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0